Molecules,
Journal Year:
2024,
Volume and Issue:
29(19), P. 4729 - 4729
Published: Oct. 7, 2024
Cancer
is
a
global
health
challenge
with
rising
incidence
and
mortality
rates,
posing
significant
concerns.
The
World
Health
Organization
reports
cancer
as
leading
cause
of
death
worldwide,
contributing
to
nearly
one
in
six
deaths.
pathogenesis
involves
disruptions
cellular
signaling
pathways,
resulting
uncontrolled
cell
growth
metastasis.
Among
emerging
players
biology,
Transient
Receptor
Potential
(TRP)
channels,
notably
TRPV1,
have
garnered
attention
due
their
altered
expression
cells
roles
tumorigenesis
progression.
also
known
the
capsaicin
receptor,
pivotal
pain
mediation,
offering
promise
therapeutic
target.
Activation
TRPV1
triggers
calcium
influx
affects
linked
death.
Additionally,
implicated
cancer-induced
chemo-sensitivity,
upregulation
observed
sensory
neurons
innervating
oral
cancers.
Also,
when
capsaicin,
compound
from
chili
peppers,
interacts
it
elicits
"hot"
sensation
influences
processes
through
influx.
Understanding
TRPV1's
multifaceted
may
lead
novel
strategies
for
managing
cancer-related
symptoms
improving
patient
outcomes.
current
review
elucidates
comprehensive
role
therapy,
particularly
channel,
highlighting
its
effects
various
via
different
pathways
discussing
limitations.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(10), P. 5489 - 5489
Published: May 17, 2024
Over
120
small-molecule
kinase
inhibitors
(SMKIs)
have
been
approved
worldwide
for
treating
various
diseases,
with
nearly
70
FDA
approvals
specifically
cancer
treatment,
focusing
on
targets
like
the
epidermal
growth
factor
receptor
(EGFR)
family.
Kinase-targeted
strategies
encompass
monoclonal
antibodies
and
their
derivatives,
such
as
nanobodies
peptides,
along
innovative
approaches
use
of
degraders
protein
interaction
inhibitors,
which
recently
demonstrated
clinical
progress
potential
in
overcoming
resistance.
Nevertheless,
kinase-targeted
encounter
significant
hurdles,
including
drug
resistance,
greatly
impacts
benefits
patients,
well
concerning
toxicity
when
combined
immunotherapy,
restricts
full
utilization
current
treatment
modalities.
Despite
these
challenges,
development
remains
highly
promising.
The
extensively
studied
tyrosine
family
has
70%
its
stages
development,
while
30%
inadequately
explored.
Computational
technologies
play
a
vital
role
accelerating
novel
repurposing
existing
drugs.
Recent
FDA-approved
SMKIs
underscore
importance
blood-brain
barrier
permeability
long-term
patient
benefits.
This
review
provides
comprehensive
summary
recent
based
mechanisms
action
targets.
We
summarize
latest
developments
new
explore
emerging
inhibition
from
perspective.
Lastly,
we
outline
obstacles
future
prospects
inhibition.
MedComm,
Journal Year:
2025,
Volume and Issue:
6(4)
Published: March 30, 2025
ABSTRACT
Signal
transducer
and
activator
of
transcription
3
(STAT3)
is
a
critical
factor
involved
in
multiple
physiological
pathological
processes.
While
STAT3
plays
an
essential
role
homeostasis,
its
persistent
activation
has
been
implicated
the
pathogenesis
various
diseases,
particularly
cancer,
bone‐related
autoimmune
disorders,
inflammatory
cardiovascular
neurodegenerative
conditions.
The
interleukin‐6/Janus
kinase
(JAK)/STAT3
signaling
axis
central
to
activation,
influencing
tumor
microenvironment
remodeling,
angiogenesis,
immune
evasion,
therapy
resistance.
Despite
extensive
research,
precise
mechanisms
underlying
dysregulated
disease
progression
remain
incompletely
understood,
no
United
States
Food
Drug
Administration
(USFDA)‐approved
direct
inhibitors
currently
exist.
This
review
provides
comprehensive
evaluation
STAT3's
health
disease,
emphasizing
involvement
cancer
stem
cell
maintenance,
metastasis,
inflammation,
drug
We
systematically
discuss
therapeutic
strategies,
including
JAK
(tofacitinib,
ruxolitinib),
Src
Homology
2
domain
(S3I‐201,
STATTIC),
antisense
oligonucleotides
(AZD9150),
nanomedicine‐based
delivery
systems,
which
enhance
specificity
bioavailability
while
reducing
toxicity.
By
integrating
molecular
mechanisms,
pathology,
emerging
interventions,
this
fills
knowledge
gap
STAT3‐targeted
therapy.
Our
insights
into
crosstalk,
epigenetic
regulation,
resistance
offer
foundation
for
developing
next‐generation
with
greater
clinical
efficacy
translational
potential.
Cardiovascular Diagnosis and Therapy,
Journal Year:
2024,
Volume and Issue:
14(6), P. 1186 - 1201
Published: Nov. 21, 2024
Interleukin-6
(IL-6)
plays
multifaceted
roles
in
cancer
and
atherosclerosis.
Initially
recognized
for
its
role
immune
response
inflammation,
IL-6
promotes
tumor
progression
via
the
JAK-STAT
MAP
kinase
pathways
is
associated
with
poor
prognoses.
In
atherosclerosis,
contributes
to
endothelial
dysfunction
plaque
formation.
This
review
highlights
shared
inflammatory
mechanisms
of
both
diseases
explores
regulatory
dynamics
signaling,
including
gene
polymorphisms
epigenetic
modifications.
Google
Scholar,
Scopus,
PubMed
were
searched
English-language
articles
on
those
reporting
pathogenic
atherosclerosis
from
their
inception
through
June
2024.
The
investigation
into
IL-6's
reveals
intricate
interconnected
nature
processes
chronic
diseases.
conditions
underscores
centrality
disease
pathology,
particularly
involvement
modulation,
cellular
proliferation.
commonality
as
a
key
player
linking
these
seemingly
distinct
Given
mechanism
this
narrative
concludes
by
emphasizing
therapeutic
potential
modulating
treating
It
advocates
personalized
treatment
strategies
that
combine
targeted
therapies
lifestyle
holistic
approach
considered
crucial
effective
management,
given
diverse
complex
widespread
conditions.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Aug. 30, 2024
T
lymphocytes
that
infiltrate
the
tumor
microenvironment
(TME)
often
fail
to
function
as
effective
anti-cancer
agents.
Within
TME,
cell-to-cell
inhibitory
interactions
play
significant
roles
in
dampening
their
anti-tumor
activities.
Recent
studies
have
revealed
soluble
factors
released
TME
by
immune
and
non-immune
cells,
well
cells
themselves,
contribute
exacerbation
of
cell
exhaustion.
Our
understanding
cytokine
landscape
interrelationships,
impact
on
cancer
development
is
still
at
its
early
stages.
In
this
review,
we
aim
shed
light
Interleukin
(IL)
-6,
IL-9,
IL-10,
a
small
group
JAK/STAT
signaling-dependent
cytokines
harboring
cell-suppressive
effects
summarize
mechanisms
action.
Additionally,
will
explore
how
advancements
scientific
research
can
help
us
overcoming
obstacles
posed
suppress
tumors,
with
ultimate
objective
stimulating
further
investigations
for
novel
therapeutic
strategies
counteract
tumor-promoting